TB Alliance launches landmark Phase 3 clinical trial aimed at shortening duration of TB treatment

TB Alliance has announced that it will conduct a landmark Phase 3 clinical trial aimed at shortening the treatment of drug sensitive and MDR-TB. The trial known as STAND (Shortening Treatments by Advancing Novel Drugs) will test the PaMZ drug regimen composed of two drug candidates not yet approved for TB, PA-824 (Pa) and moxifloxacin (M), in addition to existing antibiotic pyrazinamide (Z). The STAND trial will span over 50 sites in 4 continents and is expected to shorten the treatment of MDR-TB from 2 years to 6 months. Additional benefits of the novel regimen include its low cost and relative ease compared to existing treatments and its compatibility with HIV drugs.

The Bill and Melinda Gates Foundation has pledged financial support to TB Alliance for the STAND trial as well as the United Kingdom Department for International Development (DFID), US Agency for International Development (USAID) and other organizations.

For the official TB Alliance press release click here

Additional Coverage and Links

TB Alliance Grants Fosun Pharma Rights to Develop, Market Promising TB Cure in China

New and better drugs for MDR-TB on the horizon

More News
27 Feb 2020
ERA4TB, or European Accelerator of Tuberculosis Regime, is a public-private initiative devoted to accelerate the development of new treatmen regimens for Tuberculosis. This project integrates more than thirty organizations from the European Union and the United States among which are the main...
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...